The Relationship Between Cognitive Status and Exercise Capacity, Fatigue Perception in Coronary Artery Patients

February 23, 2024 updated by: Dilara Saklica, Hacettepe University

An Investigation of The Relationship Between Cognitive Status and Exercise Capacity, Fatigue Perception in Coronary Artery Patients

The study aimed to examine the relationship between cognitive status, exercise capacity, and fatigue perception in coronary artery disease patients.

Study Overview

Status

Completed

Conditions

Detailed Description

Exercise training for patients with coronary artery disease is an essential element of multicomponent cardiac rehabilitation. For the successful implementation of exercise-based cardiac rehabilitation programs, adequate cognitive function (e.g. executive function, selective attention, memory) is an important prerequisite. In patients with atherosclerotic coronary artery disease, the presence of coronary microvascular dysfunction as determined by low coronary flow reserve is associated with abnormal cerebral flow hemodynamics and mild but significant impairment in cognitive function. In the literature, there is no study examining the relationship between cognitive level and fatigue perception.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey
        • HACETTEPE UNIVERSİTY

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients are 18 years old and older and are diagnosed with coronary artery disease.

Description

Inclusion Criteria:

  • Volunteering to participate in the research
  • Being diagnosed with coronary artery disease
  • To cooperate with the tests to be performed
  • Signing a consent form

Exclusion Criteria:

  • Presence of neurological disease that may affect cognitive status
  • Presence of clinically unstable cardiac disease
  • Left ventricular ejection fraction <30%
  • Being diagnosed with end-stage renal failure
  • Diagnosed with active myocarditis or pericarditis
  • Being diagnosed with rhythm disorder
  • Having amputation, peripheral arterial disease, musculoskeletal and/or neurological diseases that will prevent participation in functional capacity tests
  • Not volunteering to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with Coronary Artery Disease
Having been diagnosed with coronary artery disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive State Assessment
Time Frame: August 2023-August 2024
Montreal Cognitive Assessment Scale (MoCA) will be used to assess cognitive status.
August 2023-August 2024
Assessment of Exercise Capacity
Time Frame: August 2023-August 2024
Exercise capacity will be evaluated with modified shuttle walking test.
August 2023-August 2024
Assessment of Perceived Fatigue Severity After Exercise Test
Time Frame: August 2023-August 2024
It will be evaluated on the Modified Borg Scale from 0 to 10. 0 means no fatigue. 10 means extremely tired.
August 2023-August 2024

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Activity Assessment
Time Frame: August 2023-August 2024
Physical activity level will be measured with the International Physical Activity Questionnaire (IPAQ). 600 METs (Metabolic Equivalent of Task) min/week means inactive.
August 2023-August 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hacettepe University

Investigators

  • Study Director: Naciye Vardar-Yagli, PhD, HACETTEPE UNIVERSİTY
  • Study Chair: Ahmet Hakan Ates, PhD, HACETTEPE UNIVERSİTY
  • Study Chair: Hikmet Yorgun, PhD, HACETTEPE UNIVERSİTY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Actual)

February 23, 2024

Study Completion (Actual)

February 23, 2024

Study Registration Dates

First Submitted

January 30, 2024

First Submitted That Met QC Criteria

January 30, 2024

First Posted (Actual)

February 7, 2024

Study Record Updates

Last Update Posted (Actual)

February 26, 2024

Last Update Submitted That Met QC Criteria

February 23, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GO 23/639

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe